EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Bioage Labs's enterprise value is $-167.52 Mil.
Bioage Labs's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $1.45 Mil. Therefore, Bioage Labs's EV-to-Revenue for today is -115.45.
The historical rank and industry rank for Bioage Labs's EV-to-Revenue or its related term are showing as below:
BIOA'
s EV-to-Revenue Range Over the Past 10 Years
Min: -132.5 Med: -115.45 Max: -109.28
Current: -115.45
During the past 3 years, the highest EV-to-Revenue of Bioage Labs was -109.28. The lowest was -132.50. And the median was -115.45.
BIOA's EV-to-Revenue is ranked better than 99.79% of 975
companies
in the Drug Manufacturers industry
Industry Median: 2.4
vs BIOA: -115.45
As of today (2025-05-30), Bioage Labs's stock price is $3.915.
Bioage Labs's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.04. Therefore, Bioage Labs's PS Ratio for today is 97.88.
Bioage Labs EV-to-Revenue Historical Data
The historical data trend for Bioage Labs's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bioage Labs's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Bioage Labs's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioage Labs's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bioage Labs's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Bioage Labs's EV-to-Revenue falls into.
Bioage Labs's current Enterprise Value is $-167.52 Mil.
Bioage Labs's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioage Labs's share price for today is $3.915.
Bioage Labs's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioage Labs EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Bioage Labs's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIOA has been successfully added to your 